Albumin-bound Paclitaxel (ab-pac) Versus Docetaxel for First-line Treatment of Metastatic Breast Cancer (MBC): Overall Survival (OS) Subset Analyses of a Randomized Phase 2 Trial

被引：1
|
作者：
Gradishar, W. J. [1 ]
Krasnojon, D. A. [2 ]
Cheporov, S. V. [3 ]
Makhson, A. N. [4 ]
Manikhas, G. M. [5 ]
Clawson, A. [6 ]
Bhar, P. [6 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[2] Leningrad Reg Oncol Ctr, Dept Chemotherapy, Kuzmolovo, Russia
[3] Yaroslavl Reg Clin Oncol Hosp, Dept Chemotherapy, Yaroslavl, Russia
[4] City Oncol Hosp 62, Dept Chemotherapy, Moscow, Russia
[5] St Petersburg City Oncol Ctr, Dept Chemotherapy, St Petersburg, Russia
[6] Celgene Corp, Biostat, Summit, NJ USA
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)71502-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S348 / S348
页数：1
相关论文
共 50 条
  • [1] Albumin-bound paclitaxel (ab-pac) versus docetaxel for first-line treatment of metastatic breast cancer (MBC): Final overall survival (OS) analysis of a randomized phase II trial.
    Gradishar, W. J.
    Krasnojon, D.
    Cheporov, S. V.
    Makhson, A.
    Manikhas, G. M.
    Clawson, A.
    Bhar, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
  • [2] Albumin-Bound Paclitaxel (ab-pac) Versus Docetaxel for First-Line Treatment of Metastatic Breast Cancer (MBC): Overall Survival and Safety Analysis of a Randomized Phase II Trial.
    Gradishar, W. J.
    Krasnojon, D.
    Cheporov, S.
    Makhson, A. N.
    Manikhas, G. M.
    Clawson, A.
    Bhar, P.
    CANCER RESEARCH, 2011, 71
  • [3] A Randomized Phase II Trial of First-Line Metastatic Breast Cancer (MBC) Patients: Sub-Set Analysis of Albumin-Bound Paclitaxel (ab-pac) Given Weekly at 150 mg/m2.
    Gradishar, W. J.
    Krasnojon, D.
    Cheporov, S.
    Makhson, A. N.
    Manikhas, G. M.
    Clawson, A.
    Bhar, P.
    CANCER RESEARCH, 2011, 71
  • [4] Phase II Multicenter Trial of Albumin-Bound Paclitaxel and Capecitabine in First-Line Treatment of Patients With Metastatic Breast Cancer
    Schwartzberg, Lee S.
    Arena, Francis P.
    Mintzer, David M.
    Epperson, Amanda L.
    Walker, Mark S.
    CLINICAL BREAST CANCER, 2012, 12 (02) : 87 - 93
  • [5] Phase II trial of nab-paclitaxel (nanoparticle albumin-bound paclitaxel (ABX)) plus capecitabine (XEL) in first-line treatment of metastatic breast cancer (MBC)
    Somer, B. G.
    Schwartzberg, L. S.
    Arena, F.
    Epperson, A.
    Fu, D.
    Fortner, B. V.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC)
    Conlin, A. K.
    Hudis, C. A.
    Bach, A.
    Moynahan, M.
    Lake, D.
    Forero-Torres, A.
    Wright, G.
    Hackney, M.
    Clawson, A.
    Seidman, A. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] Cost-effectiveness of nanoparticle albumin-bound paclitaxel versus docetaxel in the treatment of metastatic breast cancer.
    Gradishar, W
    Vishalpura, T
    Franklin, M
    Bramley, T
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S220 - S221
  • [8] Albumin-Bound Paclitaxel: A Review of Its Use for the First-Line Combination Treatment of Metastatic Pancreatic Cancer
    Sheridan M. Hoy
    Drugs, 2014, 74 : 1757 - 1768
  • [9] Albumin-Bound Paclitaxel: A Review of Its Use for the First-Line Combination Treatment of Metastatic Pancreatic Cancer
    Hoy, Sheridan M.
    DRUGS, 2014, 74 (15) : 1757 - 1768
  • [10] Phase II Trial of Weekly Nanoparticle Albumin-Bound Paclitaxel With Carboplatin and Trastuzumab as First-line Therapy for Women With HER2-Overexpressing Metastatic Breast Cancer
    Conlin, Alison K.
    Seidman, Andrew D.
    Bach, Ariadne
    Lake, Diana
    Dickler, Maura
    D'Andrea, Gabriella
    Traina, Tiffany
    Danso, Michael
    Brufsky, Adam M.
    Saleh, Mansoor
    Clawson, Alicia
    Hudis, Clifford A.
    CLINICAL BREAST CANCER, 2010, 10 (04) : 281 - 287
12345